Sanofi and GlaxoSmithKline will apply for regulatory approval of their long-awaited Covid-19 vaccine as a primary jab and booster, after reporting an overall efficacy rate of 57.9 per cent.
赛诺菲(Sanofi)和葛兰素史克(GlaxoSmithKline)将申请监管机构批准它们期待已久的新冠疫苗作为基础剂和加强针，此前两家公司报告的总有效性为57.9%。
您已阅读8%（274字），剩余92%（3120字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。